Cargando…

Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related glucocorticoid excess is present in ~60% of patients and associated with particularly poor prognosis. Results of first clinical trials using immune checkpoint inhibitors were heterogeneous. Here we characterize...

Descripción completa

Detalles Bibliográficos
Autores principales: Landwehr, Laura-Sophie, Altieri, Barbara, Schreiner, Jochen, Sbiera, Iuliu, Weigand, Isabel, Kroiss, Matthias, Fassnacht, Martin, Sbiera, Silviu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264832/
https://www.ncbi.nlm.nih.gov/pubmed/32474412
http://dx.doi.org/10.1136/jitc-2019-000469
_version_ 1783541012085342208
author Landwehr, Laura-Sophie
Altieri, Barbara
Schreiner, Jochen
Sbiera, Iuliu
Weigand, Isabel
Kroiss, Matthias
Fassnacht, Martin
Sbiera, Silviu
author_facet Landwehr, Laura-Sophie
Altieri, Barbara
Schreiner, Jochen
Sbiera, Iuliu
Weigand, Isabel
Kroiss, Matthias
Fassnacht, Martin
Sbiera, Silviu
author_sort Landwehr, Laura-Sophie
collection PubMed
description BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related glucocorticoid excess is present in ~60% of patients and associated with particularly poor prognosis. Results of first clinical trials using immune checkpoint inhibitors were heterogeneous. Here we characterize tumor-infiltrating T lymphocytes (TILs) in ACC in association with glucocorticoids as potential explanation for resistance to immunotherapy. METHODS: We performed immunofluorescence analysis to visualize tumor-infiltrating T cells (CD3(+)), T helper cells (CD3(+)CD4(+)), cytotoxic T cells (CD3(+)CD8(+)) and regulatory T cells (Tregs; CD3(+)CD4(+)FoxP3(+)) in 146 ACC tissue specimens (107 primary tumors, 16 local recurrences, 23 metastases). Quantitative data of immune cell infiltration were correlated with clinical data (including glucocorticoid excess). RESULTS: 86.3% of ACC specimens showed tumor infiltrating T cells (7.7 cells/high power field (HPF)), including T helper (74.0%, 6.7 cells/HPF), cytotoxic T cells (84.3%, 5.7 cells/HPF) and Tregs (49.3%, 0.8 cells/HPF). The number of TILs was associated with better overall survival (HR for death: 0.47, 95% CI 0.25 to 0.87), which was true for CD4(+)− and CD8(+) subpopulations as well. In localized, non-metastatic ACC, the favorable impact of TILs on overall and recurrence-free survival was manifested even independently of ENSAT (European Network for the Study of Adrenal Tumors) stage, resection status and Ki67 index. T helper cells were negatively correlated with glucocorticoid excess (Phi=−0.290, p=0.009). Patients with glucocorticoid excess and low TILs had a particularly poor overall survival (27 vs. 121 months in patients with TILs without glucocorticoid excess). CONCLUSION: Glucocorticoid excess is associated with T cell depletion and unfavorable prognosis. To reactivate the immune system in ACC by checkpoint inhibitors, an inhibition of adrenal steroidogenesis might be pivotal and should be tested in prospective studies.
format Online
Article
Text
id pubmed-7264832
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72648322020-06-12 Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma Landwehr, Laura-Sophie Altieri, Barbara Schreiner, Jochen Sbiera, Iuliu Weigand, Isabel Kroiss, Matthias Fassnacht, Martin Sbiera, Silviu J Immunother Cancer Basic Tumor Immunology BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related glucocorticoid excess is present in ~60% of patients and associated with particularly poor prognosis. Results of first clinical trials using immune checkpoint inhibitors were heterogeneous. Here we characterize tumor-infiltrating T lymphocytes (TILs) in ACC in association with glucocorticoids as potential explanation for resistance to immunotherapy. METHODS: We performed immunofluorescence analysis to visualize tumor-infiltrating T cells (CD3(+)), T helper cells (CD3(+)CD4(+)), cytotoxic T cells (CD3(+)CD8(+)) and regulatory T cells (Tregs; CD3(+)CD4(+)FoxP3(+)) in 146 ACC tissue specimens (107 primary tumors, 16 local recurrences, 23 metastases). Quantitative data of immune cell infiltration were correlated with clinical data (including glucocorticoid excess). RESULTS: 86.3% of ACC specimens showed tumor infiltrating T cells (7.7 cells/high power field (HPF)), including T helper (74.0%, 6.7 cells/HPF), cytotoxic T cells (84.3%, 5.7 cells/HPF) and Tregs (49.3%, 0.8 cells/HPF). The number of TILs was associated with better overall survival (HR for death: 0.47, 95% CI 0.25 to 0.87), which was true for CD4(+)− and CD8(+) subpopulations as well. In localized, non-metastatic ACC, the favorable impact of TILs on overall and recurrence-free survival was manifested even independently of ENSAT (European Network for the Study of Adrenal Tumors) stage, resection status and Ki67 index. T helper cells were negatively correlated with glucocorticoid excess (Phi=−0.290, p=0.009). Patients with glucocorticoid excess and low TILs had a particularly poor overall survival (27 vs. 121 months in patients with TILs without glucocorticoid excess). CONCLUSION: Glucocorticoid excess is associated with T cell depletion and unfavorable prognosis. To reactivate the immune system in ACC by checkpoint inhibitors, an inhibition of adrenal steroidogenesis might be pivotal and should be tested in prospective studies. BMJ Publishing Group 2020-05-30 /pmc/articles/PMC7264832/ /pubmed/32474412 http://dx.doi.org/10.1136/jitc-2019-000469 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Basic Tumor Immunology
Landwehr, Laura-Sophie
Altieri, Barbara
Schreiner, Jochen
Sbiera, Iuliu
Weigand, Isabel
Kroiss, Matthias
Fassnacht, Martin
Sbiera, Silviu
Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
title Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
title_full Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
title_fullStr Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
title_full_unstemmed Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
title_short Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
title_sort interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
topic Basic Tumor Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264832/
https://www.ncbi.nlm.nih.gov/pubmed/32474412
http://dx.doi.org/10.1136/jitc-2019-000469
work_keys_str_mv AT landwehrlaurasophie interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma
AT altieribarbara interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma
AT schreinerjochen interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma
AT sbieraiuliu interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma
AT weigandisabel interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma
AT kroissmatthias interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma
AT fassnachtmartin interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma
AT sbierasilviu interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma